Evidence supports the use of multi-gene testing as a reliable sequencing tool for the detection of mutations, including in advanced cancer [7,48], with prior research reporting that among patients with NSCLC who had previously been tested and deemed negative for EGFR and ALK mutations using single-gene strategies, 17% and 35% were identified as positive using NGS testing, respectively [49,50]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.